Optimization of Novel Indazoles as Highly Potent and Selective Inhibitors of Phosphoinositide 3-Kinase delta for the Treatment of Respiratory Disease

Optimization of lead compound 1, through extensive use of structure-based design and a focus on PI3K delta potency, isoform selectivity, and inhaled PK properties, led to the discovery of clinical candidates 2 (GSK2269557) and 3 (G5K2292767) for the treatment of respiratory indications via inhalatio...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Journal of medicinal chemistry Ročník 58; číslo 18; s. 7381 - 7399
Hlavní autoři:	Down, Kenneth, Amour, Augustin, Baldwin, Ian R., Cooper, Anthony W. J., Deakin, Angela M., Felton, Leigh M., Guntrip, Stephen B., Hardy, Charlotte, Harrison, Zoe A., Jones, Katherine L., Jones, Paul, Keeling, Suzanne E., Le, Joelle, Livia, Stefano, Lucas, Fiona, Lunniss, Christopher J., Parr, Nigel J., Robinson, Ed, Rowland, Paul, Smith, Sarah, Thomas, Daniel A., Vitulli, Giovanni, Washio, Yoshiaki, Hamblin, J. Nicole
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	WASHINGTON Amer Chemical Soc 24.09.2015
Témata:	Administration, Inhalation Animals Asthma - drug therapy Chemistry, Medicinal Female Humans Indazoles - chemistry Indazoles - pharmacokinetics Indazoles - pharmacology Isoenzymes - antagonists & inhibitors Life Sciences & Biomedicine Male Microsomes - metabolism Molecular Docking Simulation Ovalbumin - immunology Oxazoles - chemistry Oxazoles - pharmacokinetics Oxazoles - pharmacology Pharmacology & Pharmacy Phosphoinositide-3 Kinase Inhibitors Pneumonia - drug therapy Pneumonia - immunology Pulmonary Disease, Chronic Obstructive - drug therapy Rabbits Rats Rats, Sprague-Dawley Respiratory Tract Diseases - drug therapy Science & Technology Stereoisomerism Structure-Activity Relationship Sulfonamides - chemistry Sulfonamides - pharmacokinetics Sulfonamides - pharmacology Th2 Cells - immunology BLOCKERS MECHANISMS PI3K PATHWAY DISCOVERY
ISSN:	0022-2623, 1520-4804
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Shrnutí:	Optimization of lead compound 1, through extensive use of structure-based design and a focus on PI3K delta potency, isoform selectivity, and inhaled PK properties, led to the discovery of clinical candidates 2 (GSK2269557) and 3 (G5K2292767) for the treatment of respiratory indications via inhalation. Compounds 2 and 3 are both highly selective for PI3K delta over the closely related isoforms and are active in a disease relevant brown Norway rat acute OVA model of Th2-driven lung inflammation.
Bibliografie:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	0022-2623 1520-4804
DOI:	10.1021/acs.jmedchem.5b00767